David Thomas, PhD, FRACP

BIO

Dr. Thomas’ focus is on the application of genomic technologies to the understanding and management of cancer. He is Head of the Genomic Cancer Medicine Laboratory at the Garvan Institute of Medical Research, and a National Health & Medical Research Council (NHMRC) L3 Investigator. He is CEO of Omicron, a non-profit company with a national precision medicine program for patients with advanced and early onset cancers, which he established in 2019. He is also Conjoint Professor, UNSW, Sydney.

Dr. Thomas is an internationally recognized leader in his field and is especially interested in precision oncology and clinical trials, somatic and germline cancer genomics, and sarcomas and cancer in young adults. He founded the Australasian Sarcoma Study Group, a national research organization, and established Australia’s leading adolescent and young adult cancer unit at the Peter MacCallum Cancer Centre. He leads the International Sarcoma Kindred Study, and led the first international study of denosumab in Giant Cell Tumor of bone, leading to FDA and TGA approval. In 2018, he was President of the Connective Tissue Oncology Society, the peak international body in his field.

Add George Clinical to your network